Literature DB >> 25192236

Initial diagnosis of the congenital disorder of glycosylation PMM2-CDG (CDG1a) in a 4-year-old girl after neurosurgical intervention for cerebral hemorrhage.

Harald Stefanits1, Vassiliki Konstantopoulou, Magnus Kuess, Ivan Milenkovic, Christian Matula.   

Abstract

The congenital disorder of glycosylation characterized by a deficiency of phosphomannomutase 2 (PMM2-CDG) is the most common variant of congenital disorders of glycosylation. Besides typical clinical features, such as dysmorphism and abnormal body fat distribution, coagulation abnormities often lead to thromboembolic and hemorrhagic events in these patients. However, only 2 cases of intracerebral bleeding in patients with PMM2-CDG have been described so far. A 4-year-old girl who initially presented with symptoms resulting from raised intracranial pressure underwent acute neurosurgical intervention for intracranial hemorrhage. The differential diagnoses after MRI included arteriovenous malformation and intraparenchymal brain tumor. However, clinical investigations promoted the diagnosis of PMM2-CDG, which was supported further by neuropathological findings and finally confirmed by isoelectric focusing and mutational analysis. No major complications or neurological deficits were evident after surgery, and the patient was able to attend an integrated kindergarten. Unexplained intracranial hemorrhage should raise suspicion of a metabolic disorder and should be discussed with specialists to rule out an orphan disease such as PMM2-CDG.

Entities:  

Keywords:  AT III = antithrombin III; CDG = congenital disorder of glycosylation; CDG1a; PMM2 = phosphomannomutase 2; PMM2-CDG deficiency; PNET = primitive neuroectodermal tumor; disordered blood clotting; intracerebral hemorrhage; vascular disorders

Mesh:

Substances:

Year:  2014        PMID: 25192236     DOI: 10.3171/2014.7.PEDS14102

Source DB:  PubMed          Journal:  J Neurosurg Pediatr        ISSN: 1933-0707            Impact factor:   2.375


  5 in total

1.  Three families with mild PMM2-CDG and normal cognitive development.

Authors:  Mari-Anne Vals; Eva Morava; Kai Teeäär; Riina Zordania; Sander Pajusalu; Dirk J Lefeber; Katrin Õunap
Journal:  Am J Med Genet A       Date:  2017-04-19       Impact factor: 2.802

2.  Cystic kidney diseases associated with mutations in phosphomannomutase 2 promotor: a large spectrum of phenotypes.

Authors:  Guillaume Dorval; Cécile Jeanpierre; Vincent Morinière; Carole Tournant; Bettina Bessières; Tania Attié-Bittach; Jeanne Amiel; Emmanuel Spaggari; Yves Ville; Elodie Merieau; Marie-Claire Gubler; Sophie Saunier; Laurence Heidet
Journal:  Pediatr Nephrol       Date:  2021-02-13       Impact factor: 3.714

3.  Atrial septal defect in a patient with congenital disorder of glycosylation type 1a: a case report.

Authors:  Ruo-Hao Wu; Dong-Fang Li; Wen-Ting Tang; Kun-Yin Qiu; Yu Li; Xiong-Yu Liao; Dan-Xia Tang; Li-Jun Qin; Bing-Qing Deng; Xiang-Yang Luo
Journal:  J Med Case Rep       Date:  2018-01-24

4.  In Vitro Fertilisation (IVF) Associated with Preimplantation Genetic Testing for Monogenic Diseases (PGT-M) in a Romanian Carrier Couple for Congenital Disorder of Glycosylation Type Ia (CDG-Ia): A Case Report.

Authors:  Bogdan Doroftei; Loredana Nemtanu; Ovidiu-Dumitru Ilie; Gabriela Simionescu; Iuliu Ivanov; Emil Anton; Maria Puiu; Radu Maftei
Journal:  Genes (Basel)       Date:  2020-06-25       Impact factor: 4.096

5.  Synaptic roles for phosphomannomutase type 2 in a new Drosophila congenital disorder of glycosylation disease model.

Authors:  William M Parkinson; Michelle Dookwah; Mary Lynn Dear; Cheryl L Gatto; Kazuhiro Aoki; Michael Tiemeyer; Kendal Broadie
Journal:  Dis Model Mech       Date:  2016-03-03       Impact factor: 5.758

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.